epcoritamab
abbvie,genmab
['fil,veral,12', 'epcoritamab', 'lymsm', 'dlbcl']
congress | #ash22 , shared results from a study of epcoritamab, a bispecific ab in combo with salvage immunochemotherapy in pts with r/r dlbcl eligible for asct. pts enrolled were highly refractory. cr of 67% was observed. median os was not met.
#lymsm 
A global education platform providing clinical updates on a range of lymphoma subtypes and chronic lymphocytic leukemia (#CLL) #lymsm